Annotated test-retest dataset of lung cancer CT scan images reconstructed at multiple imaging parameters by Binsheng Zhao, Laurent Dercle, Hao Yang, Gregory J. Riely, Mark G. Kris, Lawrence H. Schwartz

Get full text

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. by William Pao, Theresa Y Wang, Gregory J Riely, Vincent A Miller, Qiulu Pan, Marc Ladanyi, Maureen F Zakowski, Robert T Heelan, Mark G Kris, Harold E Varmus

Get full text

Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers. by Bob T Li, Emil Lou, Meier Hsu, Helena A Yu, Jarushka Naidoo, Marjorie G Zauderer, Camelia Sima, Melissa L Johnson, Mariza Daras, Lisa M DeAngelis, Martin Fleisher, Mark G Kris, Christopher G Azzoli

Get full text

Deep learning of cell spatial organizations identifies clinically relevant insights in tissue images by Shidan Wang, Ruichen Rong, Qin Zhou, Donghan M. Yang, Xinyi Zhang, Xiaowei Zhan, Justin Bishop, Zhikai Chi, Clare J. Wilhelm, Siyuan Zhang, Curtis R. Pickering, Mark G. Kris, John Minna, Yang Xie, Guanghua Xiao

Get full text

Phase I trial of the TNF-α inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas by Paul K. Paik, Jia Luo, Ni Ai, Rachel Kim, Linda Ahn, Anup Biswas, Courtney Coker, Wanchao Ma, Phillip Wong, Darren J. Buonocore, W. Victoria Lai, Jamie E. Chaft, Swarnali Acharyya, Joan Massagué, Mark G. Kris

Get full text

Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy by Akane Inoue-Yamauchi, Paul S. Jeng, Kwanghee Kim, Hui-Chen Chen, Song Han, Yogesh Tengarai Ganesan, Kota Ishizawa, Sylvia Jebiwott, Yiyu Dong, Maria C. Pietanza, Matthew D. Hellmann, Mark G. Kris, James J. Hsieh, Emily H. Cheng

Get full text

Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. by Jenifer L Marks, Michael D McLellan, Maureen F Zakowski, Alex E Lash, Yumi Kasai, Stephen Broderick, Inderpal S Sarkaria, Duykhanh Pham, Bhuvanesh Singh, Tracie L Miner, Ginger A Fewell, Lucinda L Fulton, Elaine R Mardis, Richard K Wilson, Mark G Kris, Valerie W Rusch, Harold Varmus, William Pao

Get full text

Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer by Shidan Wang, Ruichen Rong, Donghan M. Yang, Junya Fujimoto, Justin A. Bishop, Shirley Yan, Ling Cai, Carmen Behrens, Lynne D. Berry, Clare Wilhelm, Dara Aisner, Lynette Sholl, Bruce E. Johnson, David J. Kwiatkowski, Ignacio I. Wistuba, Paul A. Bunn Jr., John Minna, Guanghua Xiao, Mark G. Kris, Yang Xie

Get full text

ctDNA-based detection of molecular residual disease in stage I-III non-small cell lung cancer patients treated with definitive radiotherapy by Emily S. Lebow, Emily S. Lebow, Narek Shaverdian, Jordan E. Eichholz, Leah B. Kratochvil, Megan McCune, Yonina R. Murciano-Goroff, Yonina R. Murciano-Goroff, Justin Jee, Justin Jee, Juliana Eng, Juliana Eng, Jamie E. Chaft, Mark G. Kris, Mark G. Kris, Ekaterina Kalashnikova, Jordan Feeney, Carly Bess Scalise, Sumedha Sudhaman, Charuta C. Palsuledesai, Meenakshi Malhotra, Michael Krainock, Himanshu Sethi, Alexey Aleshin, Minetta C. Liu, Annemarie F. Shepherd, Abraham J. Wu, Charles B. Simone, Daphna Y. Gelblum, Kaylie A. Johnson, Charles M. Rudin, Charles M. Rudin, Daniel R. Gomez, Pedram Razavi, Pedram Razavi, Jorge S. Reis-Filho, James M. Isbell, James M. Isbell, Bob T. Li, Bob T. Li, Andreas Rimner

Get full text

Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study by Yuan Chen, Biagio Ricciuti, Matthew D Hellmann, Hira Rizvi, Mark M Awad, Giuseppe Lamberti, Arielle Elkrief, Jamie E Chaft, Xinan Wang, Samantha Brown, Charles M Rudin, Joao M Victor Alessi, Isabel R Preeshagul, Federica Pecci, Alessandro Di Federico, Jacklynn V Egger, Gregory J Riely, Mark G Kris, Marc Ladanyi, Ronglai Shen, Adam J Schoenfeld

Get full text

Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations by Kathryn C. Arbour, MD, Eusebio Manchado, PhD, Matthew J. Bott, MD, Linda Ahn, NP, Yosef Tobi, BA, Andy Ai Ni, Helena A. Yu, MD, Alyssa Shannon, BA, Marc Ladanyi, MD, Victoria Perron, BS, Michelle S. Ginsberg, MD, Amanda Johnson, BA, Andrei Holodny, MD, Mark G. Kris, MD, Charles M. Rudin, MD, PhD, Piro Lito, MD, PhD, Neal Rosen, MD, PhD, Scott Lowe, PhD, Gregory J. Riely, MD, PhD

Get full text

Brief Report: Clinical Characteristics and Outcomes of Patients With Thoracic SMARCA4-Deficient Undifferentiated Tumors by Alissa J. Cooper, MD, Andrea Arfe, PhD, Biagio Ricciuti, MD, Andréanne Gagné, MD, PhD, Lynette M. Sholl, MD, Alessandro Di Federico, MD, Mark M. Awad, MD, PhD, Mihaela Aldea, MD, PhD, Maria Rosa Ghigna, MD, Miruna Grecea, MD, Phoebe Clark, MS, Jamie E. Chaft, MD, Mark G. Kris, MD, Gregory J. Riely, MD, Charles M. Rudin, MD, PhD, Ibiayi Dagogo-Jack, MD, Mari Mino-Kenudson, MD, Lingzhi Hong, MD, PhD, Neda Kalhor, MD, Natalie Vokes, MD, Anita Bowman, MS, Soo-Ryum Yang, MD, Natasha Rekhtman, MD, PhD, Adam J. Schoenfeld, MD

Get full text